Lilly plans massive new investment in US production facilities

US pharma major Eli Lilly (NYSE: LLY) plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical manufacturing sites in the USA, involving new investment of $27 billion.

This brings the company's total US capital expansion commitments to more than $50 billion since 2020, Lilly announced at a press conference in Washington DC today.

Three of the future US sites announced today will focus on manufacturing active pharmaceutical ingredients (API), reshoring critical capabilities of small molecule chemical synthesis and further strengthening Lilly's supply chain. These include compounds such as tirzepatide, the active ingredient in Lilly’s obesity drug Zepbound and diabetes treatment Mounjaro. The combined sales of the two dugs last year amount to $16.46 billion. The fourth location will extend the company's global parenteral manufacturing network for future injectable therapies.